Johnson & Johnson (J&J) will invest $500m to eliminate HIV and tuberculosis by two. The company said it will appoint a research team to use J&J's resources and decades of experience with the 2030 diseases to identify, develop and deliver next-generation vaccines and treatments. The initiative will also fulfil the UN's Sustainable Development Goal 3 targets, and includes the Janssen Pharmaceutical Companies' investigational mosaic-based global vaccine trial.
Johnson & Johnson (J&J) will invest $500m to eliminate HIV and tuberculosis by 2030. The company said it will appoint a research team to use J&J's resources and decades of experience with the two diseases to identify, develop and deliver next-generation vaccines and treatments. The initiative will also fulfil the UN's Sustainable Development Goal 3 targets, and includes the Janssen Pharmaceutical Companies' investigational mosaic-based global vaccine trial.